

CLINICAL CANCER RESEARCH

TABLE OF CONTENTS

HIGHLIGHTS

- 1 Selected Articles from This Issue

SPECIAL FEATURES

CCR Translations

- 3 **CDK4/6 Inhibitor Biomarker Research: Are We Barking Up the Wrong Tree?**
Meenakshi Anurag, Svasti Haricharan, and Matthew J. Ellis
See related article, p. 110
- 6 **Metabolic Subtyping for Novel Personalized Therapies Against Pancreatic Cancer**
Kamiya Mehla and Pankaj K. Singh
See related article, p. 135
- 9 **A Solution to the Dilution: The Role for Biomarkers in Advanced Ovarian Cancer**
Katelyn F. Handley and Anil K. Sood
See related article, p. 213

Review


- 11 **Immune Activation in Mismatch Repair–Deficient Carcinogenesis: More Than Just Mutational Rate**
Jason A. Willis, Laura Reyes-Urbe, Kyle Chang, Steven M. Lipkin, and Eduardo Vilar

CLINICAL TRIALS: TARGETED THERAPY

- 18 **Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using *UGT1A1* Genotype–Guided Dosing**
Smita S. Joshi, Daniel V.T. Catenacci, Theodore G. Karrison, Jaclyn D. Peterson, Mark M. Zalupski, Amikar Sehdev, James Wade, Ahad Sadiq, Vincent J. Picozzi, Andrea Amico, Robert Marsh, Mark F. Kozloff, Blase N. Polite, Hedy L. Kindler, and Manish R. Sharma

- 25 **Selective Progesterone Receptor Modulators in Early-Stage Breast Cancer: A Randomized, Placebo-Controlled Phase II Window-of-Opportunity Trial Using Telapristone Acetate**
Oukseub Lee, Megan E. Sullivan, Yanfei Xu, Chiara Rogers, Miguel Muzzio, Irene Helenowski, Ali Shidfar, Zexian Zeng, Hari Singhal, Boroko Jovanovic, Nora Hansen, Kevin P. Bethke, Peter H. Gann, William Gradishar, J. Julie Kim, Susan E. Clare, and Seema A. Khan

- 35 **Randomized Phase 0/I Trial of the Mitochondrial Inhibitor ME-344 or Placebo Added to Bevacizumab in Early HER2-Negative Breast Cancer**
Miguel Quintela-Fandino, Serafin Morales, Alfonso Cortés-Salgado, Luis Manso, Juan V. Apala, Manuel Muñoz, Ariadna Gasol Cudos, Joel Salla Fortuny, María Gion, Antonio Lopez-Alonso, Javier Cortés, Juan Guerra, Diego Malón, Eduardo Caleiras, Francisca Mulero, and Silvana Mouron

- 46 **Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in *BRAF*-Mutant Melanoma**
 Antoni Ribas, Adil Daud, Anna C. Pavlick, Rene Gonzalez, Karl D. Lewis, Omid Hamid, Thomas F. Gajewski, Igor Puzanov, Matthew Wongchenko, Isabelle Rooney, Jessie J. Hsu, Yibing Yan, Erica Park, and Grant A. McArthur

- 54 **Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia**
Kendra Sweet, Rami Komrokji, Eric Padron, Christopher L. Cubitt, Joel G. Turner, Junmin Zhou, Alan F. List, David A. Sallman, Jana L. Dawson, Daniel M. Sullivan, Julio Chavez, Bijal D. Shah, and Jeffrey E. Lancet

TABLE OF CONTENTS

CLINICAL TRIALS: IMMUNOTHERAPY

- 61 Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy**

A C Padmanee Sharma, Joohyuk Sohn, Sang Joon Shin, Do-Youn Oh, Bhumsuk Keam, Hyo Jin Lee, Marco Gizzi, Ewa Kalinka, Filip Y.F.L. de Vos, Dario Ruscica, Salvatore Ferro, Feng Xiao, Paul Baverel, Cecil Chi-Keung Chen, Kobby Asubonteng, Nassim Morsli, and Luc Dirix

- 71 Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study**

A C Devalingam Mahalingam, Grey A. Wilkinson, Kevin H. Eng, Paul Fields, Patrick Raber, Jennifer L. Moseley, Karol Cheetham, Matt Coffey, Gerard Nuovo, Pawel Kalinski, Bin Zhang, Sukeshi Patel Arora, and Christos Fountzilas

PRECISION MEDICINE AND IMAGING

- 82 Purity Independent Subtyping of Tumors (PurIST), A Clinically Robust, Single-sample Classifier for Tumor Subtyping in Pancreatic Cancer**

Naim U. Rashid, Xianlu L. Peng, Chong Jin, Richard A. Moffitt, Keith E. Volmar, Brian A. Belt, Roheena Z. Panni, Timothy M. Nywening, Silvia G. Herrera, Kristin J. Moore, Sarah G. Hennessey, Ashley B. Morrison, Ryan Kawalerski, Apoorve Nayyar, Audrey E. Chang, Benjamin Schmidt, Hong Jin Kim, David C. Linehan, and Jen Jen Yeh

- 93 DNA Methylation Profiling Identifies Distinct Clusters in Angiosarcomas**

Marije E. Weidema, Ellen van de Geer, Christian Koelsche, Ingrid M.E. Desar, Patrick Kemmeren, Melissa H.S. Hillebrandt-Roeffen, Vincent K.Y. Ho, PALGA Group, Winette T.A. van der Graaf, Yvonne M.H. Versleijen-Jonkers, Andreas von Deimling, and Uta E. Flucke

- 101 Sex Disparity Observed for Oncotype DX Breast Recurrence Score in Predicting Mortality Among Patients with Early Stage ER-Positive Breast Cancer**

Fei Wang, Sonya Reid, Wei Zheng, Tuya Pal, Ingrid Meszoely, Ingrid A. Mayer, Christina E. Bailey, Ben Ho Park, and Xiao-Ou Shu

- 110 Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naïve Metastatic Breast Cancer**

A C Richard S. Finn, Yuan Liu, Zhou Zhu, Miguel Martin, Hope S. Rugo, Véronique Diéras, Seock-Ah Im, Karen A. Gelmon, Nadia Harbeck, Dongrui R. Lu, Eric Gauthier, Cynthia Huang Bartlett, and Dennis J. Slamon

See related commentary, p. 3

- 122 Detection of Circulating and Disseminated Neuroblastoma Cells Using the ImageStream Flow Cytometer for Use as Predictive and Pharmacodynamic Biomarkers**

Swathi Merugu, Lindi Chen, Elizabeth Gavens, Hany Gabra, Mark Brougham, Guy Makin, Antony Ng, Dermot Murphy, Alem S. Gabriel, Michael L. Robinson, Jennifer H. Wright, Susan A. Burchill, Angharad Humphreys, Nick Bown, David Jamieson, and Deborah A. Tweddle

- 135 Altered Gene Expression along the Glycolysis-Cholesterol Synthesis Axis Is Associated with Outcome in Pancreatic Cancer**

Joanna M. Karasinska, James T. Topham, Steve E. Kalloger, Gun Ho Jang, Robert E. Denroche, Luka Culibrk, Laura M. Williamson, Hui-Li Wong, Michael K.C. Lee, Grainne M. O’Kane, Richard A. Moore, Andrew J. Mungall, Malcolm J. Moore, Cassia Warren, Andrew Metcalfe, Faiyaz Notta, Jennifer J. Knox, Steven Gallinger, Janessa Laskin, Marco A. Marra, Steven J.M. Jones, Daniel J. Renouf, and David F. Schaeffer

See related commentary, p. 6

- 147 Ultrasmall Core-Shell Silica Nanoparticles for Precision Drug Delivery in a High-Grade Malignant Brain Tumor Model**

Rupa Juthani, Brian Madajewski, Barney Yoo, Li Zhang, Pei-Ming Chen, Feng Chen, Melik Z. Turker, Kai Ma, Michael Overholtzer, Valerie A. Longo, Sean Carlin, Virginia Aragon-Sanabria, Jason Huse, Mithat Gonen, Pat Zanzonico, Charles M. Rudin, Ulrich Wiesner, Michelle S. Bradbury, and Cameron W. Brennan

- 159 A Transcriptionally Definable Subgroup of Triple-Negative Breast and Ovarian Cancer Samples Shows Sensitivity to HSP90 Inhibition**

Kevin Shee, Jason D. Wells, Matthew Ung, Riley A. Hampsch, Nicole A. Traphagen, Wei Yang, Stephanie C. Liu, Megan A. Zeldenrust, Liewei Wang, Krishna R. Kalari, Jia Yu, Judy C. Boughey, Eugene Demidenko, Arminja N. Kettenbach, Chao Cheng, Matthew P. Goetz, and Todd W. Miller

- 171 Comprehensive Transcriptomic Profiling Identifies Breast Cancer Patients Who May Be Spared Adjuvant Systemic Therapy**

A C Martin Sjöström, S. Laura Chang, Nick Fishbane, Elai Davicioni, Linda Hartman, Erik Holmberg, Felix Y. Feng, Corey W. Speers, Lori J. Pierce, Per Malmström, Märten Fernö, and Per Karlsson

TABLE OF CONTENTS

- 183 MRI Tumor Regression Grade and Circulating Tumor DNA as Complementary Tools to Assess Response and Guide Therapy Adaptation in Rectal Cancer**
Shelize Khakoo, Paul David Carter, Gina Brown, Nicola Valeri, Simona Picchia, Maria Antonietta Bali, Ridwan Shaikh, Thomas Jones, Ruwaida Begum, Isma Rana, Andrew Wotherspoon, Monica Terlizzo, Katharina von Loga, Eleftheria Kalaitzaki, Claire Saffery, David Watkins, Diana Tait, Ian Chau, Naureen Starling, Michael Hubank, and David Cunningham
- 193 Phosphoproteomic and Kinomic Signature of Clinically Aggressive Grade I (1.5) Meningiomas Reveals RB1 Signaling as a Novel Mediator and Biomarker**
A C Carolina A. Parada, Joshua W. Osburn, Tina Busald, Yigit Karasozen, Sumanpreet Kaur, Min Shi, Jason Barber, Widya Adidharma, Patrick J. Cimino, Catherine Pan, Luis F. Gonzalez-Cuyar, Robert Rostomily, Donald E. Born, Jing Zhang, and Manuel Ferreira Jr
- 206 Bevacizumab Reduces Permeability and Concurrent Temozolomide Delivery in a Subset of Patients with Recurrent Glioblastoma**
Elizabeth R. Gerstner, Kyrre E. Emblem, Ken Chang, Bella Vakulenko-Lagun, Yi-Fen Yen, Andrew L. Beers, Jorg Dietrich, Scott R. Plotkin, Ciprian Catana, Jacob M. Hooker, Dan G. Duda, Bruce Rosen, Jayashree Kalpathy-Cramer, Rakesh K. Jain, and Tracy Batchelor
- 213 Dilution of Molecular-Pathologic Gene Signatures by Medically Associated Factors Might Prevent Prediction of Resection Status After Debulking Surgery in Patients With Advanced Ovarian Cancer**
Florian Heitz, Stefan Kommoss, Roshan Tourani, Anthony Grandelis, Locke Uppendahl, Constantin Aliferis, Alexander Burges, Chen Wang, Ulrich Canzler, Jinhua Wang, Antje Belau, Sonia Prader, Lars Hanker, Sisi Ma, Beyhan Ataseven, Felix Hilpert, Stephanie Schneider, Jalid Sehouli, Rainer Kimmig, Christian Kurzeder, Barbara Schmalfeldt, Elena I. Braicu, Philipp Harter, Sean C. Dowdy, Boris J. Winterhoff, Jacobus Pfisterer, and Andreas du Bois
See related commentary, p. 9
- 232 CD200 Checkpoint Reversal: A Novel Approach to Immunotherapy**
A C Zhengming Xiong, Elisabet Ampudia Mesias, G. Elizabeth Pluhar, Susan K. Rathe, David A. Largaespada, Yuk Y. Sham, Christopher L. Moertel, and Michael R. Olin
- 242 Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer**
Gonzalo Recondo, Laura Mezquita, Francesco Facchinetti, David Planchard, Anas Gazzah, Ludovic Bigot, Ahsan Z. Rizvi, Rosa L. Frias, Jean Paul Thiery, Jean-Yves Scoazec, Tony Sourisseau, Karen Howarth, Olivier Deas, Dariia Samofalova, Justine Galissant, Pauline Tesson, Floriane Braye, Charles Naltet, Pernelle Lavaud, Linda Mahjoubi, Aurélie Abou Lovergne, Gilles Vassal, Rastilav Bahleda, Antoine Hollebecque, Claudio Nicotra, Maud Ngo-Camus, Stefan Michiels, Ludovic Lacroix, Catherine Richon, Nathalie Auger, Thierry De Baere, Lambros Tselikas, Eric Solary, Eric Angevin, Alexander M. Eggermont, Fabrice Andre, Christophe Massard, Ken A. Olausson, Jean-Charles Soria, Benjamin Besse, and Luc Friboulet
- 256 ARID5B Influences Antimetabolite Drug Sensitivity and Prognosis of Acute Lymphoblastic Leukemia**
Heng Xu, Xujie Zhao, Deepa Bhojwani, Shuyu E, Charnise Goodings, Hui Zhang, Nita L. Seibel, Wentao Yang, Chunliang Li, William L. Carroll, William E. Evans, and Jun J. Yang
- 265 Identification of FES as a Novel Radiosensitizing Target in Human Cancers**
Byoung Hyuck Kim, Yong Joon Kim, Myung-Ho Kim, Yi Rang Na, Daun Jung, Seung Hyeok Seok, Joon Kim, and Hak Jae Kim
- 274 Role of KEAP1/NFE2L2 Mutations in the Chemotherapeutic Response of Patients with Non-Small Cell Lung Cancer**
Youngtae Jeong, Jessica A. Hellyer, Henning Stehr, Ngoc T. Hoang, Xiaomin Niu, Millie Das, Sukhmani K. Padda, Kavitha Ramchandran, Joel W. Neal, Heather Wakelee, and Maximilian Diehn
- 282 A Validation Study on IDO Immune Biomarkers for Survival Prediction in Non-Small Cell Lung Cancer: Radiation Dose Fractionation Effect in Early-Stage Disease**
Weili Wang, Lei Huang, Jian-Yue Jin, Wenhu Pi, Susannah G. Ellsworth, Shruti Jolly, Andrew L. Mellor, Mitchell Machtay, and Feng-Ming (Spring) Kong
- 290 Targeting EZH2 Enhances Antigen Presentation, Antitumor Immunity, and Circumvents Anti-PD-1 Resistance in Head and Neck Cancer**
Liye Zhou, Tenny Mudianto, Xiaojing Ma, Rachel Riley, and Ravindra Uppaluri

TRANSLATIONAL CANCER MECHANISMS AND THERAPY

- 220 Neoadjuvant Therapy Remodels the Pancreatic Cancer Microenvironment via Depletion of Protumorigenic Immune Cells**
A C Carmen Mota Reyes, Steffen Teller, Alexander Muckenhuber, Björn Konukiewitz, Okan Safak, Wilko Weichert, Helmut Friess, Güralp O. Ceyhan, and Ihsan Ekin Demir

TABLE OF CONTENTS

301 **A PI3K/AKT Scaffolding Protein, IQ Motif-Containing GTPase Associating Protein 1 (IQGAP1), Promotes Head and Neck Carcinogenesis**

Tao Wei, Suyong Choi, Darya Buehler,
Richard A. Anderson, and Paul F. Lambert

EDITOR'S NOTE

312 **Editor's Note: Sulforaphane Enhances the Therapeutic Potential of TRAIL in Prostate Cancer Orthotopic Model through Regulation of Apoptosis, Metastasis, and Angiogenesis**

Sharmila Shankar, Suthakar Ganapathy, and
Rakesh K. Srivastava


313 **Acknowledgment to Reviewers**

AC AC icon indicates AuthorChoice

For more information please visit www.aacrjournals.org

ABOUT THE COVER

The cover shows a section of the tumor core of a patient with pancreatic cancer. Immunofluorescence staining with ki67 shows the proliferating cells within the tumor on primarily resected patients. For details, see the article by Mota Reyes and colleagues on page 220 of this issue.



Clinical Cancer Research

26 (1)

Clin Cancer Res 2020;26:1-322.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/26/1>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/26/1>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.